Initial Avon/NCI breast cancer research grants awarded in 'Progress for Patients' awards program
...se inhibitors as a prevention tool, new methods of radioimmunotherapy for women with metastatic disease, as well as other areas of research. The Progress for Patients program was launched in October 2001 when the NCI received a $20 million pledge from the Avon Foundation to fund translational research on breast cancer....New radioimmunotherapy cancer treatment
...rapy. Their study compared low-dose rituxan-based radioimmunotherapy (RIT) with a high-dose regimen of the same therapy. Seven of eight patients who received the high-dose RIT had a complete remission, compared to only one of four with low dose. The remaining high-dose person had a partial remission. At the time of...New radioimmunotherapy drug proves highly effective for killing off B cell non-Hodgkins lymphoma
...icates the first of a new class of drugs involving radioimmunotherapy benefited a significant number of patients with lo...on-Hodgkins lymphoma B cells. Zevalin is the first radioimmunotherapy drug developed specifically to fight this common but usually fatal cancer of the lymph glands that, ...Bexxar highly effective as first-line treatment for patients with non-Hodgkin's lymphoma
...first completed study of a first-line, stand-alone radioimmunotherapy for cancer, were presented today at the meeting of...homa, a disease without a known cure." Bexxar is a radioimmunotherapy that combines a mouse monoclonal antibody attached to radioactive iodine 131. It attaches to a prote...